BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 15601560)

  • 1. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
    Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ
    Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunochemotherapy: the new standard in aggressive non-Hodgkin's lymphoma in the elderly.
    Coiffier B
    Semin Oncol; 2003 Feb; 30(1 Suppl 2):21-7. PubMed ID: 12652461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical features, therapeutic responses, and prognosis of the patients with mantle cell lymphoma.
    Ying ZT; Zheng W; Wang XP; Xie Y; Tu MF; Lin NJ; Ping LY; Liu WP; Deng LJ; Zhang C; Zhu J; Song YQ
    Chin J Cancer; 2012 Jul; 31(7):348-53. PubMed ID: 22704490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pixantrone beyond monotherapy: a review.
    Barrenetxea Lekue C; Grasso Cicala S; Leppä S; Stauffer Larsen T; Herráez Rodríguez S; Alonso Caballero C; Jørgensen JM; Toldbod H; Leal Martínez I; D'Amore F
    Ann Hematol; 2019 Sep; 98(9):2025-2033. PubMed ID: 31312929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus involvement is a predictive factor for the resistance to chemoradiotherapy of gastric diffuse large B-cell lymphoma.
    Yoshino T; Nakamura S; Matsuno Y; Ochiai A; Yokoi T; Kitadai Y; Suzumiya J; Tobinai K; Kobayashi Y; Oda I; Mera K; Ohtsu A; Ishikura S
    Cancer Sci; 2006 Feb; 97(2):163-6. PubMed ID: 16441428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy combinations with monoclonal antibodies in non-Hodgkin's lymphoma.
    Kahl B
    Semin Hematol; 2008 Apr; 45(2):90-4. PubMed ID: 18381103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy.
    Maeshima AM; Taniguchi H; Nomoto J; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Matsuno Y
    Cancer Sci; 2009 Jan; 100(1):54-61. PubMed ID: 19038008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab-combined anthracycline-free chemotherapy in newly diagnosed paediatric and adolescent patients with non-high-risk aggressive mature B cell lymphoma: protocol for a single-arm, open-label, multicentre, phase II study (the Japan Children's Cancer Group Multicentre Trial, JPLSG B-NHL-20).
    Sekimizu M; Fukano R; Koga Y; Mitsui T; Fujita N; Mori T; Hori D; Tanaka M; Ohki K; Iwafuchi H; Nakazawa A; Mori T; Kobayashi R; Hashimoto H; M Saito A; Kamei M;
    BMJ Open; 2024 Mar; 14(3):e080762. PubMed ID: 38508620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children.
    Minard-Colin V; Aupérin A; Pillon M; Burke GAA; Barkauskas DA; Wheatley K; Delgado RF; Alexander S; Uyttebroeck A; Bollard CM; Zsiros J; Csoka M; Kazanowska B; Chiang AK; Miles RR; Wotherspoon A; Adamson PC; Vassal G; Patte C; Gross TG; ;
    N Engl J Med; 2020 Jun; 382(23):2207-2219. PubMed ID: 32492302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High monocytic MDSC signature predicts multi-drug resistance and cancer relapse in non-Hodgkin lymphoma patients treated with R-CHOP.
    Dhar S; Chakravarti M; Ganguly N; Saha A; Dasgupta S; Bera S; Sarkar A; Roy K; Das J; Bhuniya A; Ghosh S; Sarkar M; Hajra S; Banerjee S; Pal C; Saha B; Mukherjee KK; Baral R; Bose A
    Front Immunol; 2023; 14():1303959. PubMed ID: 38304256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal dosage of rituximab for children with Burkitt lymphoma.
    Huang S; Jin L; Yang J; Zhang M; Zhang Y; Peng Y; Duan Y; Zheng H
    Ann Hematol; 2024 Mar; 103(3):893-903. PubMed ID: 38091052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel CD20 monoclonal antibodies for lymphoma therapy.
    Cang S; Mukhi N; Wang K; Liu D
    J Hematol Oncol; 2012 Oct; 5():64. PubMed ID: 23057966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy and safety of rituximab in children and adolescents with mature B-cell non-Hodgkin's lymphoma: a Meta analysis].
    Li BY; Han YH; Yin CY; DU WC; Li YF; Wang YC
    Zhongguo Dang Dai Er Ke Za Zhi; 2023 Jan; 25(1):51-59. PubMed ID: 36655664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20
    Munoz J; Flinn IW; Cohen JB; Sachs J; Exter B; Ranger A; Harris P; Payumo F; Nath R; Hamadani M; Westin JR; Bachanova V
    Transplant Cell Ther; 2024 Feb; 30(2):241.e1-241.e8. PubMed ID: 37898374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The FACT-targeted drug CBL0137 enhances the effects of rituximab to inhibit B-cell non-Hodgkin's lymphoma tumor growth by promoting apoptosis and autophagy.
    Lv Y; Du Y; Li K; Ma X; Wang J; Du T; Ma Y; Teng Y; Tang W; Ma R; Wu J; Wu J; Feng J
    Cell Commun Signal; 2023 Jan; 21(1):16. PubMed ID: 36691066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD20 expression regulates CD37 levels in B-cell lymphoma - implications for immunotherapies.
    Bobrowicz M; Kusowska A; Krawczyk M; Zhylko A; Forcados C; Slusarczyk A; Barankiewicz J; Domagala J; Kubacz M; Šmída M; Dostalova L; Marhelava K; Fidyt K; Pepek M; Baranowska I; Szumera-Cieckiewicz A; Inderberg EM; Wälchli S; Granica M; Graczyk-Jarzynka A; Majchrzak M; Poreba M; Gehlert CL; Peipp M; Firczuk M; Prochorec-Sobieszek M; Winiarska M
    Oncoimmunology; 2024; 13(1):2362454. PubMed ID: 38846084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma.
    Koh LP; Lim LC; Thng CH
    Med Oncol; 2000 Aug; 17(3):225-8. PubMed ID: 10962535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis.
    Dunleavy K; Hakim F; Kim HK; Janik JE; Grant N; Nakayama T; White T; Wright G; Kwak L; Gress R; Tosato G; Wilson WH
    Blood; 2005 Aug; 106(3):795-802. PubMed ID: 15718416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose methotrexate, thiotepa, orelabrutinib combined with or without rituximab in primary or secondary central nervous system diffuse large B-cell lymphoma: a single-center retrospective analysis.
    Li Y; Li Y; Zeng R; He Y; Liang L; Ou L; Su C; Zhou H; Xiao L
    J Cancer; 2023; 14(17):3182-3190. PubMed ID: 37928429
    [No Abstract]   [Full Text] [Related]  

  • 20. Rituximab in the treatment of non-Hodgkin's lymphoma.
    Hauptrock B; Hess G
    Biologics; 2008 Dec; 2(4):619-33. PubMed ID: 19707443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.